Ivabradina Ciclum

Ivabradine Hydrochloride, the active ingredient in Ivabradina Ciclum, is a If channel inhibitor presented as an oral dosage form for oral use. It is indicated for chronic stable angina and heart failure with reduced ejection fraction in appropriate adult patients.

GNH USA supplies Ivabradina Ciclum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradina Ciclum, an If channel inhibitor, is used in cardiovascular conditions where heart rate reduction is beneficial. - Chronic stable angina: reduces the frequency of angina attacks and improves exercise tolerance. - Heart failure with reduced ejection fraction: lowers heart rate, improving symptoms and decreasing hospitalization risk.

Ivabradina Ciclum may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects: - Visual disturbances (phosphenes): transient luminous phenomena. - Headache. - Dizziness. - Mild bradycardia.

Serious or Rare Side Effects: - Severe bradycardia leading to syncope. - Atrial fibrillation. - Hepatic enzyme elevation.

When prescribing Ivabradina Ciclum, clinicians should observe the following precautions. - Monitor heart rate: obtain baseline and periodic measurements. - Avoid in severe hepatic impairment: dose adjustment not recommended. - Caution in sick sinus syndrome or AV block: contraindicated. - Use with other heart‑rate‑lowering agents cautiously: risk of excessive bradycardia. - Pregnancy and lactation: safety not established; use only if benefit outweighs risk. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Ivabradina Ciclum can interact with other medicines, requiring attention to avoid clinically significant effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ivabradine plasma levels. - Co‑administration with other If channel blockers (e.g., digoxin): risk of excessive heart‑rate reduction. - Concomitant use with potent CYP3A4 inducers (e.g., rifampicin): may markedly reduce efficacy.

Moderate Interactions (Monitor Closely): - Beta‑blockers: additive bradycardic effect. - Calcium‑channel blockers (verapamil, diltiazem): increase ivabradine exposure. - Selective serotonin reuptake inhibitors (e.g., fluoxetine): moderate CYP3A4 inhibition may raise drug levels.